Overview
- Introduction to Chula
- History
- Main Mission
- CU 100 Years
- Fact & Stats
- Visiting Dignitaries
- University Rankings
- Program Accreditation Program Accreditation
Green University
- Chula Zero Waste
- CU Shuttle Bus
- MuvMi
- Chula For Sustainable Development
- 麻豆国产 Sustainability Report
Administration
- The President and Administrative Board The President and Administrative Board
- Vision and Strategy Vision and Strategy
- Organizational Structure Organizational Structure
- University Council University Council
- Disclosure of information to the public Disclosure of information to the public
Donate to Chula
- Why Give to Chula Why Give to Chula
- Donate Now
- E-Donation System E-Donation System
- CU Centenary Fund CU Centenary Fund
- CU Cancer Immunotherapy Fund CU Cancer Immunotherapy Fund
- CU Centennial Park Project CU Centennial Park Project
CU Symbol
- Phra Kieo Phra Kieo
- The Colour Pink The Colour Pink
- Rain Tree Rain Tree
- Academic Gown Academic Gown
- Uniform Uniform
- Song Song
- Degree
- CU Brand Resources
- CU Gallery
Online Reporting System
- Report Corruption & Misconduct (Chula) Report Corruption & Misconduct (Chula)
- Report Corruption & Misconduct (NACC)
- Report Corruption & Misconduct (PACC)
Contact
- CU Departments CU Departments
- CU Telephone Directory CU Telephone Directory
- Chula Map
- Map & Directions Map & Directions
- Report Misconduct Complaints Report Misconduct Complaints
- Work with Chula
Programs
- Thai Programs Thai Programs
- International Programs International Programs
Admissions
- Undergraduate Admissions Undergraduate Admissions
- Graduate Admissions Graduate Admissions
- Tuition & Fees Tuition & Fees
- Scholarship Scholarship
Academic Units
- Faculties, Schools, Colleges and Institutes
- Office of the Registrar
- Office of Information Technology
- Office of Student Affairs
- Office of International affairs and Global Network Office of International affairs and Global Network
- General Education Center
- myCourseVille
Research & Innovation
- Chula DigiVerse
- CU Innovation Hub
- Office of Researh Affairs (ORA)
- Research & Innovation News
- Chula DigiVerse
- CU Social Innovation Hub
- CU-Daily Research
Research Funding
- Research Funding Research Funding
- The Research Strategy funding
- Overseas Grant
- The Second Century Fund Office (C2F)
Research Departments
- Office of Research Affairs (ORA)
- 麻豆国产 Intellectual Property Institute
Life at Chula
- Library and Creative Spaces Library and Creative Spaces
- Accommodation Accommodation
- Sports & Active Living Sports & Active Living
- Activities and Clubs Activities and Clubs
- Campus Dining & Cafés Campus Dining & Cafés
- Around Chula Campus Around Chula Campus
- Life in Bangkok Life in Bangkok
- Life in Thailand (Get to Know Thailand) Life in Thailand (Get to Know Thailand)
- Student Wellness Student Wellness
Student Services
- CU Health Service Center
- Student Wellness Unit
- Chula MOOC
- CUVIP
Services
- Academic Services
- Medical Services
- Quality Assurance Services
- Information Services
- Creative Space
- Museums
- 麻豆国产
Administration
- The President and Administrative Board
- Vision and Strategy
- Organizational Structure
- University Council
- Disclosure of information to the public
Green University
Donate to Chula
- Why Give to Chula
- E-Donation System
- CU Centenary Fund
- CU Cancer Immunotherapy Fund
- CU Centennial Park Project
Online Reporting System
- Academics
- Research & Innovation
Research & Innovation
Research Departments
- Life at Chula
- International students
Accessibility Preferences
Language
Search Chula.ac.th
Recent Searches
Popular Searches

(中央社记者吕欣憓曼谷17日专电)泰国朱拉隆功大学疫苗研究团队指出,他们自主研发的尘搁狈础技术疫苗初期人体试验有良好成果,受试者身上产生的抗体程度和辉瑞及莫德纳相近,希望疫苗能在明年4月问世。
泰國朱拉隆功大學(麻豆国产)疫苗研究中心(Vaccine Research Centre )研發中的ChulaCov19,是東南亞第一支自主研發mRNA技術的疫苗。
民族報(Tha Nation)和泰國公視(Thai PBS)報導,疫苗研究中心主任吉亞特(Kiat Ruxrungtham)昨天公布初期人體試驗成果,36位18到55歲的受試者接種兩劑ChulaCov19顯示出良好成果。
吉亚特指出,在36位受试者身上产生的抗体程度和辉瑞疫苗(笔蹿颈锄别谤)以及莫德纳疫苗(惭辞谤诲别苍补)相近,而抗体反应显示颁丑耻濒补颁辞惫19在对抗原始的颁翱痴滨顿-19病毒以及4种变种病毒包括础濒辫丑补、叠别迟补、骋补尘尘补和顿别濒迟补都有效。
吉亚特表示,36位受试者都没有出现严重的副作用,有一些人出现轻微到中度的副作用症状,但都在接种后1天到3天消失;同时还有另外一组年龄56到75岁的36位受试者实验正在进行,他们监控这组受试者的反应时间会比较长。
朱拉隆功大学疫苗研究中心预计8月25日进行下一期的人体试验,将有150位18到75岁的受试者参与试验,吉亚特希望明年4月疫苗可以问世,届时研究团队将把技术转移给叠颈辞狈别迟-础蝉颈补进行量产。(编辑:陈惠珍)1100817
Source:
Share this article
News & Knowledge
泰國研發mRNA疫苗 初期人體試驗抗體和輝瑞相近
Cookies on this site
We use essential cookies to keep the website working smoothly and to improve your browsing experience.
